Merz Pharmaceuticals, LLC Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity
10/6/2009 10:07:53 AM
More...
|
Merz Pharmaceuticals, LLC's Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
9/11/2009 10:59:03 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Announces Termination of its License and Cooperation Agreement with Merz Pharmaceuticals, LLC and Children's Medical Center
8/12/2009 6:43:47 AM
More...
|
DiaGenic ASA to Provide MCI Biomarkers for Merz Pharmaceuticals, LLC
6/24/2009 9:07:48 AM
More...
|
Merz Pharmaceuticals, LLC Announce Three Studies of NT-201
6/9/2009 9:05:53 AM
More...
|
Merz Pharmaceuticals, LLC Announces Results of Clinical Trials with NT-201
6/8/2009 9:44:29 AM
More...
|
Merz Pharmaceuticals, LLC Release: First-Ever Standardized Scales to Measure the Skin's Aging Process Are Introduced at the American Society for Aesthetic Plastic Surgery's Annual Meeting
5/4/2009 11:17:36 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5/4/2009 7:54:45 AM
More...
|
Merz Pharmaceuticals, LLC Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
4/28/2009 11:29:01 AM
More...
|
Merz Pharmaceuticals, LLC Release: New Xeomin(TM), Now Indicated in Canada for Blepharospasm, Cervical Dystonia(i), and Post-Stroke Spasticity
3/27/2009 9:39:07 AM
More...
|
|